Benzinga | Jun 15, 2021 07:18AM EDT

Cerevel Therapeutics Announces Fast Track Designation Granted By The FDA To CVL-871 For The Treatment Of Dementia-Related Apathy

Cerevel Therapeutics (NASDAQ:CERE), a company dedicated to unraveling the mysteries of the brain to treat neuroscience diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to CVL-871, a D1/D5 partial agonist in development for the treatment of dementia-related apathy.